ONCAlert | Upfront Therapy for mRCC

Biomarker-Driven Lung Cancer VIEW MORE >>

Oncologists have unanswered questions about how to deal with resistance mechanisms for multikinase inhibitors and selective RET inhibitors, and how efficacy is impacted when they combine 2 or more such drugs into a treatment regimen for RET-positive lung cancer. In a paper, researchers led by Vivek Subbiah, et al review the existing data.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.